Miglustat
- Part D specialty tier in 83% of formularies (2026Q3)
- OPFOLDA
Therapy management checklist
Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.
Loading the therapy management checklist…
Storage and cold chain
Miglustat: storage and handling
- Freezing
- Not addressed
- Room temperature
- at or below 30°C (86°F)
Label statement
Excursions are permitted between 15°C to 30°C (59°F to 86°F), [see USP Controlled Room Temperature].
- Room temperature
- at or below 25°C (77°F)
Label statement
Store OPFOLDA at room temperature between 68°F to 77°F (20°C to 25°C).
- Back into the refrigerator
- Not addressed
- Light
- Protect from light
Label statement
Store in the original container to protect from light.
- Shaking
- Not addressed
All storage statements on the label (4)
- Excursions are permitted between 15°C to 30°C (59°F to 86°F), [see USP Controlled Room Temperature].
- Store in the original container to protect from light.
- Store OPFOLDA at room temperature between 68°F to 77°F (20°C to 25°C).
- Keep OPFOLDA capsules in the original container to protect from light.
FDA label version 5, effective November 27, 2024. DailyMed
Dosing and titration calendar
Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.
Loading dosing schedules…
Medicare Part D coverage
5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan
Patient assistance
No manufacturer program page is listed for this drug yet.
Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.
For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.